SCHEMBL21807437

SCHEMBL21807437

O=c1[nH]ncc(N2CCc3c(ccnc3Oc3ccc(F)cc3C(F)(F)F)C2)c1Cl

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 17/20 0.77
TRPC4 Q9UBN4 2/20 0.77
TIPARP Q7Z3E1 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807255 0.87 TRPC5 (1.00) TRPC5TRPC4
SCHEMBL21807457 0.86 TRPC5 (0.78) TRPC5TRPC4TIPARP
SCHEMBL24433279 0.83 TRPC5 (0.71) TRPC5TRPC4
SCHEMBL29330810 0.83 TRPC5 (0.78) TRPC5TRPC4
SCHEMBL21832180 0.82 TRPC5 (0.70) TRPC5TRPC4
SCHEMBL22002418 0.82 TRPC5 (0.77) TRPC5TRPC4
SCHEMBL29329704 0.82 TRPC5 (0.91) TRPC5TRPC4
SCHEMBL27124756 0.82 TRPC5 (0.76) TRPC5TRPC4
SCHEMBL21807303 0.82 TRPC5 (0.76) TRPC5TRPC4TIPARP
SCHEMBL27119533 0.81 TRPC5 (0.75) TRPC5TRPC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113939295-B Pyridazinones and methods of use thereof 金翅雀生物公司 2025-05-16 CN disclosed
EP-4414365-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2024-08-14 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 US disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
EP-3941475-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2022-01-26 EP disclosed
CN-113939295-A Pyridazinones and methods of use thereof 金翅雀生物公司 2022-01-14 CN disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
CN-112911935-A Pyridazinones and methods of use thereof 金翅雀生物公司 2021-06-04 CN disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-04-02 US disclosed
WO-2020061162-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885TIPARP 4068/4885
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GLS, ATP6V1B1, PDXK TRPC5 3626/4885TRPC4 4095/4885TIPARP 3438/4885
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885TIPARP 4068/4885
US-11046690-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885TIPARP 4068/4885
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885TIPARP 4068/4885
US-10654850-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN TRPC5 2486/4885TRPC4 3512/4885TIPARP 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.